BioCentury | Aug 19, 2017
Product Development

Restoring dependence

...NP137, Netris’ NP413 is a mAb targeting semaphorin 3E (SEMA3E) , the ligand of the plexin D1 (PLXND1)...
BioCentury | Nov 14, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Semaphorin 3E (SEMA3E); plexin D1 (PLXND1)...
...and diabetes. In a mouse model of diet-induced obesity, expression of Sema3e and its receptor, Plxnd1...
...tissue than that seen in nondiabetic controls. In the mouse model, Sema3e inhibition with soluble Plxnd1...
BioCentury | Apr 28, 2011
Distillery Therapeutics

Indication: Ophthalmic disease

...SEMA3E-PLXND1 signaling could help treat ischemic retinopathy. In developing mice, Sema3e deficiency or disruption of Plxnd1...
...normalized vascular growth compared with injection of control protein. Planned work includes investigating agonists of Sema3e-Plxnd1...
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Cancer

...SEMA3E); plexin D1 (PLXND1) In vitro and mouse studies suggest that inhibiting SEMA3E or antagonizing its receptor, PLXND1...
...cancer metastasis. In human metastatic carcinoma cells implanted into mice, small hairpin RNA-mediated knockdown of PLXND1...
Items per page:
1 - 4 of 4